Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.790
+0.050 (2.87%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Gain Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
25
Market Cap
50.02M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
GANX News
- 22 days ago - Gain Therapeutics Announces Poster Presentation at AD/PD 2025 - GlobeNewsWire
- 23 days ago - Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update - GlobeNewsWire
- 5 weeks ago - Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease - GlobeNewsWire
- 6 weeks ago - Gain Therapeutics Announces Oral Presentation at AD/PD 2025 - GlobeNewsWire
- 2 months ago - Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update - GlobeNewsWire
- 2 months ago - Gain Therapeutics To Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results - Seeking Alpha
- 4 months ago - Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease - GlobeNewsWire